Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies - ATC Abstracts
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial - The Lancet
Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients - Hartinger - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Long-term Efficacy and Safety of Everolimus Versus Mycopheno... : Transplantation
De Novo Therapy with Everolimus and Low-Dose Calcineurin Inhibitors in Kidney Transplantation | Semantic Scholar
Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil | PLOS ONE
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions - ScienceDirect
Everolimus dose and trough blood levels, and laboratory values for... | Download Scientific Diagram
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR) | PLOS ONE
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review | SpringerLink
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Enhanced Humoral Immune Response After COVID-19 Vaccination... : Transplantation
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Full article: The use of everolimus in renal-transplant patients
IJMS | Free Full-Text | Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study - American Journal of Transplantation
An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients - ScienceDirect
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Figure 1 from Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients | Semantic Scholar
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients | PLOS ONE
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial - American Journal of Transplantation
Use of everolimus in liver transplantation
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - ScienceDirect
